Cytological specimens from thyroid nodules are increasingly being adopted as the first available material for cost effectively managing patients in the era of personalized medicine. Cytology aspirates not only play a central role in providing accurate diagnoses, but are also being collected for ancillary molecular testing. Molecular analysis, including the evalua- 
INTRODUCTION
Fine needle aspiration cytology (FNAC) plays a central role in the evaluation of thyroid nodules. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In this last decade, several studies have shown that the application of ancillary techniques, such as molecular testing, complement FNAC in the management of thyroid nodules, including thyroid cancer. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] Expanding knowledge of the genomic landscape for thyroid carcinoma has demonstrated that molecular alterations are linked to the development of tumorigenesis, histotypes with more aggressive tumor behavior, and tumor recurrence. 38, 39 Several publications have suggested that the results of molecular analysis performed on FNAC guide patient management as an additional tool for diagnosis, therapy, and prognosis. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [40] [41] [42] [43] In fact, molecular evaluation of FNAC may help to refine the risk of malignancy for tailored therapy and/or lead to alternative management strategies. Despite the controversy of cost-effectiveness, which limits the adoption of molecular testing by several laboratories around the world, advances in the application of ancillary techniques of cytological material have been encouraged by the ensuing reduction of cost and diminished concerns related to obtaining good quantity and quality DNA/RNA. 44 Cytology procedures provide well-preserved DNA that is readily extractable and reasonably stable (from 6 months to 5 years) regardless of the cytological preparation (eg, freshly prepared, unstained/stained direct smears, air-dried or alcohol-fixed slides,
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and liquid-based cytology). Liquid-based cytology (LBC) thyroid specimens subjected to molecular testing have demonstrated feasible and valid results. [45] [46] [47] [48] [49] [50] As an example, Chang et al 51 reported 84.9% sensitivity for BRAF molecular mutation in a series of thyroid LBC cases that were positive for malignancy. Even though formalin-fixed samples offer good results in the application of ancillary techniques, formalin is associated with important flaws, including interference with the degradation of nucleic acids, structural damage, and fragmentation in the process of DNA extraction. [44] [45] [46] The possible aid offered by molecular testing in the practice of thyroid cytology was addressed in recent updates of the management of thyroid nodules in the 2nd edition of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and the 2015 American Thyroid Association (ATA) guidelines. [52] [53] [54] These guidelines specify that for adult patients with thyroid nodules, molecular tests might be added to possibly stratify the risk of malignancy (ROM) in thyroid indeterminate nodules and thereby avoid unnecessary diagnostic lobectomies and/or thyroidectomies. Although the ATA did not endorse any specific molecular test, the recently published 2nd edition of the TBSRTC suggests the potential role of different tests in different categories and diagnostic scenarios. 52, 53 However, Ferris et al 54 have suggested different molecular testing for these various diagnostic FNAC categories. It is therefore becoming increasingly important for cytologists to be aware of the varied molecular tests available in thyroid cytopathology as well as their indications, significance and limitations. This review provides an overview of the practical use of molecular testing in different thyroid lesions including implications of the introduction of noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP). 55 Briefly, in 2015 the endocrine pathology society suggested revising the diagnosis of the encapsulated, noninvasive follicular variant of papillary thyroid carcinoma (eFVPC) and renaming them as NIFTP. This new entity was defined by a specific set of morphological features characterized by a follicular growth pattern with nuclear features of papillary thyroid carcinoma (PTC), scant nuclear pseudo-inclusions as well as lack of papillary structures and psammoma bodies. 55 This review critically analyzes the role of commercially available molecular tests for resolving the indeterminate diagnostic categories of thyroid cytopathology, including their correlation with entities such as the histological diagnosis of NIFTP.
MOLECULAR PROFILING OF THYROID LESIONS
According to the literature, thyroid nodules are frequently detected in the adult population. Even though thyroid nodules are discovered with ultrasound guidance in up to 70% of the general population, only 5% to 15% of them are malignant. Fortunately, the majority of thyroid lesions are correctly diagnosed as either benign (70% to 75%) or malignant (5% to 10%) entities by thyroid fine needle aspiration (FNA). [1] [2] [3] [4] [5] The remaining nodules (20% to 25%) represent the "gray zone" of follicular/indeterminate lesions that belong to indeterminate categories according to TBSRTC. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Difficulties and limitations in morphologically discriminating whether these nodules are benign or malignant entities has led to unnecessary surgical resections (lobectomy or total thyroidectomy) and has raised health care costs accordingly. 4, 5 Patients with indeterminate nodules that undergo surgical resection often turn out to have benign thyroid nodules or only indolent neoplasms, including NIFTP. NIFTP includes cases of indeterminate FNA previously diagnosed on histopathology as FVPC. [55] [56] [57] [58] [59] [60] The discrimination between benign and malignant thyroid lesions often requires documentation of vascular and capsular invasion, which cannot be established by cytological evaluation alone.
Different classification systems, including the Bethesda, British, Italian, Japanese, and Australasia reporting systems, have attempted to refine the diagnosis of thyroid lesions, each adopting diagnostic subcategories associated with specific morphological features. 52, [61] [62] [63] [64] In TBSRTC, indeterminate neoplasms comprise 3 different subgroups: atypia of undetermined significance/follicular lesions of undetermined significance (AUS/FLUS), suspicious for follicular neoplasm/follicular neoplasm (SFN/FN), and suspicious for malignancy (SFM). 52 Each of these subcategories carries a specific ROM: 5% to 15% for AUS/FLUS; 15% to 30% for SFN/FN, and 60% to 75% for SM. This ROM is too high to be ignored, even knowing that subjecting a patient to subsequent surgery is likely to result in a benign diagnosis in 85%, 70%, and 25% of cases, respectively. In the second edition of TBSRTC, these ranges have been revised especially for the "indeterminate" categories. 52 In fact, according to the second edition, the ROM was different: 10% to 30%
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for AUS/FLUS, 25% to 40% for SFN/FN, and 50% to 75% for SFM. Nonetheless, the reclassification of some thyroid neoplasms as NIFTP led to a difference in ROM, specifically: 6% to 18% for AUS/FLUS, 10% to 40% for SFN/FN, and 45% to 60% for SFM. 52 To overcome some of the limitations of cytomorphology, numerous authors have encouraged and proposed the application of molecular analysis with thyroid FNAC. [24] [25] [26] [27] [28] There are specific mutations that occur in different thyroid carcinomas (Table 1 ). In 2014, the Thyroid Cancer Genome Atlas defined several oncogenic mutations showing that most papillary thyroid cancers, the most frequent thyroid malignant tumor, can be scored along a spectrum of either "BRAF V600E -like or "RASlike" gene expression profiles. 40 However, the high specificity of BRAF V600E mutation, RET/PTC1 and RET/ PTC3 rearrangements makes them feasible as cytological indicators of cancer regardless of the diagnostic category. 22, [26] [27] [28] [29] [30] [31] [32] [33] 40 Moreover, the detection of specific somatic mutations, gene rearrangements, and/or microRNA (miRNA) expression profiles also has high predictive value for malignant thyroid disease. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] 40, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] The utility of analyzing these mutations as different panels has been validated previously by Nikiforov and colleagues. [34] [35] [36] [37] In these reports, the investigators highlighted the advantage of using a broad next-generation sequencing (NGS) panel that provides a highly accurate, informative, and more comprehensive analysis of somatic mutations and chromosomal rearrangements in the diagnosis of nodules with AUS/FLUS and SFN/FN cytology, which ultimately facilitates the optimal management of these patients. 35, 36 An international survey in 2015 of members from the Endocrine Society, ATA, and American Association of Clinical Endocrinologists revealed that more than 50% of participants perform molecular testing with thyroid cytology in their clinical practice. 77 However, currently there is no single, unequivocal molecular approach for the preoperative assessment of thyroid nodules. Instead, the field is characterized by several noncommercial (in-house) and commercially available molecular panels for thyroid nodules. Table 2 ).
MOLECULAR TEST OPTIONS AND MOLECULAR APPROACH TO INDETERMINATE THYROID LESIONS
In the new version of TBSRTC, molecular testing was included for the indeterminate cytological diagnoses of AUS/FLUS, SFN/FN, and SFM. 52 In fact, the relevance of molecular testing and the introduction of NIFTP are two of the main reasons TBSRTC was revised recently. Similar recommendations concerning molecular testing of thyroid FNAC were also incorporated in the ATA guidelines. 53, 54 This recent acknowledgement of the role of molecular testing formalizes their use in defining risk stratification of patients with thyroid nodules. In this review, we discuss the clinical implications of the different molecular tests in the indeterminate Bethesda categories. 22, 23, [32] [33] [34] [35] [36] [37] 42, [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] It is important to note that the literature to date generally supports employing a combination of morphology and molecular testing to best guide the clinical or surgical approach for patients diagnosed with indeterminate thyroid nodules ( Table 3) .
The category of AUS/FLUS was retained in the 2017 revision of TBSRTC. 52 The exact ROM figure for this diagnostic category remains challenging. Because only a minority of patients diagnosed with AUS/FLUS undergo surgical resection, the evaluation of ROM based on resected nodules is often overestimated. For AUS/ FLUS, a repeat FNAC or consensus cytology review of the case may help reach a final definitive diagnosis, as only about 10% to 30% of initially diagnosed AUS/ FLUS nodules are again reported as AUS/FLUS when FNAC is repeated. However, a number of molecular approaches have also been studied to help further resolve the AUS/FLUS interpretation 54, [83] [84] [85] [86] [87] [88] (Table 3 ).
The recent revision of the Bethesda System proposed only minor changes for the terminology and criteria of SFN/FN. However, the major features and criteria for SFN/FN remain identical. 52 The majority of patients who are given a cytologic diagnosis of SFN/FN undergo diagnostic surgical excision (ie, lobectomy).
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Several authors have demonstrated that the likelihood of an SFN/FN nodule being neoplastic is 65% to 85%, whereas that for the ROM is significantly lower (25% to 40%). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Most of these malignancies are interpreted histologically as PTC (Fig. 1) , comprising mostly FVPC (Table 3) . Furthermore, in some cases, the expression of genetic alterations with high specificity for cancers (eg, BRAF V600E and TERT mutations) are virtually diagnostic of cancer and increased the risk of disease recurrence, indicating that these patients might benefit from more extensive surgery-including, for instance, central lymph node dissection and/or total thyroidectomy. 26, 27, 38 In the following sections, we discuss the different molecular tests employed in helping resolve lesions that fall into the Bethesda indeterminate diagnostic categories. . 32 In their seminal paper involving 1056 indeterminate follicular lesions, the authors found an increased ROM for mutated AUS/FLUS, FN, and SM cases (88%, 87%, and 95% respectively), compared with 6%, 14%, and 28% in mutation-negative lesions. 32 In that series, their cohort included 653 cytological cases of AUS/FLUS 32 with 247 that had histological follow-up. The detection of any mutations increased cancer risk from 14% to 87%, whereas the absence of any mutations was linked with a cancer risk , and 1 with PAX8/PPARγ. Twenty-two mutation-positive FNAC (88%) were from malignant nodules; they had 3 falsepositive nodules (all with RAS mutations), which were follicular adenomas. For the AUS/FLUS category, they reported 63% sensitivity, 99% specificity, 94% diagnostic accuracy, 88% PPV, and 94% NPV. They concluded that molecular analysis for a panel has significant diagnostic value for all the indeterminate categories, and a sample from a thyroid nodule that tested positive implied that such a patient should undergo surgery regardless of the Bethesda category. 32 Nikiforov and colleagues applied a molecular test employing next-generation sequencing (NGS) technology (Table 4) . [34] [35] [36] In 2013, this group of investigators evaluated targeted NGS as a new approach for testing a broad spectrum of point mutations and validated the use of a mutational panel (ThyroSeq) that included 15 genes. 34 They sequenced and analyzed DNA obtained Cancer Cytopathology August 2018 from 228 thyroid neoplastic and nonneoplastic samples, including 52 thyroid aspirations that were not specifically subclassified. 34 In fact, ThyroSeq v.1 was able to successfully analyze 99.6% of samples using 5 to 10 ng of input DNA with a sensitivity of 3% to 5% of mutant allele. 34 The panel showed that BRAF and RAS followed by PIK3CA, TP53, TSHR, PTEN, GNAS, CTNNB1, and RET were the most common mutations in their cohort. 34 In 2014, a new and superior NGS-based assay (ThyroSeq v.2) was applied initially to 143 cases of SFN/ FN. 35 Furthermore, this molecular approach was adopted in the analysis of pediatric thyroid lesions to optimize patient management. In fact, as found by Picarsic et al, 82 In the FNA validation set, the sensitivity was 98.0%, the specificity was 81.8%, and the accuracy was 90.9%. Table 4 shows that as the number of gene markers has increased with different versions of ThyroSeq over the years, the sensitivity of this test has consequently improved ( All BRAF and PAX8/PPARγ-positive nodules were malignant. Overall, 33 out of 38 mutation-positive nodules (87%) were found to be histologically malignant, whereas 5 (13%) were RAS-positive benign follicular adenomas. For this group of SFN/FN patients, the correlation between the results of mutational analysis on FNAC and outcome was 57% sensitivity, 97% specificity, 86% diagnostic accuracy, 87% PPV, and 86% NPV. 32 The same authors adopted the use of ThyroSeq v.2 in a series of 143 SFN/FN nodules, including 91 retrospectively and 52 prospectively collected cases with an overall prevalence of malignancy of 27%. Combining the entire cohort of cases, ThyroSeq v.2 showed a performance of 90% sensitivity, 93% specificity, 83% PPV, and 96% NPV. 35 Furthermore, point mutations in TERT promoter mutations) would select patients for total thyroidectomy. However, the detection of a RAS mutation, BRAFK601E mutation, and/or wild-type results would instead support only lobectomy. Despite the fact that "classical" FN exhibits moderate to marked cellularity and scant or absent colloid, some authors have described cases comprising microfollicular cellularity with a background of moderate to an abundant amount of colloid. 52, 95 For these latter cases, the application of molecular testing may be useful. Ohori et al 95 found that for such "colloid-rich" SFN/FN cases, a greater proportion of these cases harbor a mutation compared with typical (colloid-poor) SFN/FN cases. Concerning Hürthle cell nodules, the application of mutational analysis is generally unhelpful in discriminating Hürthle cell carcinoma from adenoma. RET/PTC1-3 rearrangements and RAS mutations have been reported in both Hürthle cell adenomas and carcinomas, and PAX8/ PPARγ rearrangements are very rare in Hürthle cell carcinomas.
MOLECULAR TESTING AND THE INDETERMINATE CATEGORIES (AUS/ FLUS AND SFN/FN)
BRAF V600E , TERT,
Afirma Gene Expression and Sequencing Classifier
The Afirma GEC is a commonly used molecular test for indeterminate thyroid proliferations. 37, [83] [84] [85] [86] [87] [88] [89] [90] The Afirma GEC uses a microarray device to measure the activity of over 100 genes. It is mostly used to predict benign lesions (ie, "rule in" benign diagnoses). The key validation study published by Alexander et al 37 was a multicenter trial involving 265 indeterminate thyroid lesions out of 4812 FNAC cases. The Afirma test analyzed the expression of 167 genes including 142 genes in the main classifier (benign or suspicious) and 25 smaller gene expression panels to filter out rare neoplasms. 37 The microarray technology employed works in a locked algorithm involving 2 steps. The first step was based on the use of 6 "cassettes" including 25 genes for "rare neoplasms" such as metastases, parathyroid tissue, medullary thyroid carcinoma (MTC), and oncocytic neoplasia. 37 The allocation of the sample in 1 of these 25 cassettes leads to the automatic diagnosis of "suspicious" or an "Afirma MTC" result. The device proceeds to the second step and the sample will be classified as "benign" or "suspicious" based on a proprietary Cancer Cytopathology August 2018 algorithm, using the remaining 142-gene expression profile. It is important to note that the Afirma GEC does not provide information about specific genetic alterations, even though 2 specific Afirma BRAF and Afirma MTC tests were released.
In the seminal validation paper by Alexander and colleagues in 2012, the authors reported 95% NPV for AUS/FLUS lesions and 94% in those thyroid nodules diagnosed as FN with associated malignancy rates of 24% and 25%, respectively. The Afirma GEC reduced the ROM mostly for AUS/FLUS and SFN/FN categories, whereas for SM it reported 85% NPV and 76% PPV respectively; hence, its use for SFM is not recommended. 37 Recently, the next-generation Afirma Genomic Sequencing Classifier (GSC) has been developed to better identify patients who could avoid unnecessary surgery. The Afirma GSC combines RNA sequencing and machine learning to leverage more enriched, previously undetectable genomic information. This includes not only gene expression, but also the presence of DNA variants, fusions, copy number variants, and other information that may be predictive of thyroid cancer.
Researchers validated the Afirma GSC on a prospective, multicenter, blinded cohort of 191 indeterminate samples that were the same sample set used to validate the first-generation Afirma GEC. Data shared by Dr. Kepal N. Patel demonstrate that the Afirma GSC maintained the original test's high sensitivity (91% vs 90%) and increased its specificity significantly (from 52% to 68%). The enhanced classifier's high specificity can identify 30% more patients with benign nodules compared with the Afirma GEC, allowing approximately 70% of patients with benign nodules to avoid unnecessary surgery when the cytopathology report is indeterminate.
In the evaluation of AUS/FLUS, Baca et al 87 assessed that the performance characteristics of Afirma GEC testing vary, depending on qualifiers of cytologic atypia. In their series of 227 AUS nodules with GEC testing, the rate of benign GEC results was higher in AUS nodules with architectural atypia (65%) than in AUS with nuclear atypia (59%) or AUS with both nuclear and architectural atypia (38%). In addition, the risk of cancer among patients who had GEC-suspicious nodules was higher in cases with both architectural and nuclear atypia (57%) than in cases with architectural or nuclear atypia alone (19% and 45%, respectively). The investigators concluded that the performance of GEC testing varies depending on the features of atypia. The optimal management of AUS/FLUS nodules still presents a clinical dilemma, and repeat cytology is endorsed as one strategy for management. However, as suggested by the investigators, GEC may add some information to improve preoperative risk stratification of thyroid nodules with AUS/FLUS diagnosis. The usefulness of Afirma for nodules in the AUS/ FLUS category is not as straightforward, because surgery is not recommended for follow-up. However, according to these yields for AUS/FLUS cases with nuclear atypia, the Afirma test may support a diagnostic lobectomy. Several studies indicate that approximately 46% to 50% of AUS/FLUS nodules would be classified as benign with Afirma GEC. [83] [84] [85] [86] [87] [88] [89] [90] Therefore, these patients would only need to be followed up clinically without surgery. A benign Afirma GEC result is more frequent in cases with architectural than nuclear atypia. Afirma testing is less helpful for those AUS/FLUS cases in which surgery is the first option, such as patients who have nodules larger than 4 cm, patients with compressive symptoms, or patients who opt for surgical intervention up front. In cases with a suspicious Afirma GEC result, surgery should not be performed without considering other factors (eg, nodule size, ultrasonographic findings). Hang et al 42 analyzed the role of Afirma GEC in a series of 384 indeterminate lesions, including 304 cases of AUS/FLUS and 80 cases of SFN/FN. In their AUS/FLUS category, 152 (50%) cases had a suspicious Afirma GEC result, 141 (46%) nodules had a benign result, and 11 (4%) cases had insufficient material for molecular evaluation. The investigators found that the ROM in their AUS/FLUS cases with a suspicious Afirma GEC was 42%, whereas the rate of neoplasms was 67%. No malignant case in their AUS/ FLUS cohort had a benign Afirma GEC result. 42 There was also a high total thyroidectomy rate (135 patients in the AUS group) reported in this study, likely attributed to the large proportion of cases with a suspicious Afirma GEC result. With Afirma testing, low specificity has been described, as well as some reports of false negative and controversial test results with oncocytic lesions. McIver et al, 83 in a series of 72 samples, demonstrated that the GEC test indeed had a lower than expected rate of benign results among FN and/or Hürthle cell neoplasms and a lower than anticipated malignancy rate within Afirma GECsuspicious nodules. However, it is important to underline Cancer Cytopathology August 2018 that the Afirma company reported that the recently updated version of the Afirma (GSC), commercially offered since 2017, should be able to improve performance for Hürthle-cell lesions with an increased specificity of 59% compared with just 12% with the original Afirma GEC.
Nevertheless, several authors have justified the expense of this test when evaluating the cost-effectiveness of repeat FNAC and/or surgery versus Afirma testing. [89] [90] [91] Dedhia et al estimated that the standard application of Afirma GEC ensured only a 7.2% reduction in thyroidectomies, especially among AUS/FLUS and FN lesions. 84 Kloos 85 emphasized that Afirma GEC test sensitivity among indeterminate nodules is 90%. Furthermore, Kloos highlighted that, whereas a GEC-suspicious result raises the risk of cancer from 24%-25% to 37%-38%, the value of the test is that it identifies just over one half of all benign nodules, with Bethesda III or IV cases being genomically benign and 90% of all cancers being genomically suspicious regardless of cancer prevalence. On the other hand, Harrison et al 86 confirmed the low predictive value of Afirma in their indeterminate thyroid nodules. Marti et al, 88 in a bi-institutional study involving
Memorial Sloan Kettering Cancer Center and Mount Sinai Beth Israel New York, reported different rates of malignancy in indeterminate thyroid nodules. The GEC did not routinely alter management in either institution. They noted that the Afirma GEC assay would be expected to be most informative in practice settings where the prevalence of malignancy is 15% to 21%, such that the NPV is >95% and the PPV is >25%. These investigators concluded that, at a particular institution, knowing the prevalence of malignancy in indeterminate lesions is essential for reliable interpretation of GEC results.
RosettaGX Reveal
This microRNA-based diagnostic assay is also used to further evaluate cytologically indeterminate thyroid nodules. Reports claim that this test helps prevent over 75% of unnecessary surgeries for patients with initial indeterminate cytology interpretations. Unlike other commercially available molecular tests, this test does not require a fresh FNA sample or special conditions, and can be performed on a single, routinely prepared FNA smear, stained with a Papanicolaou stain or Romanowskytype stains (Diff-Quik and Giemsa). As emphasized by Lithwick et al, 92 the test measures a set of miRNAs via quantitative reverse-transcription polymerase chain reaction to classify a nodule as benign or suspicious for malignancy by miRNA profiling, which also includes an miRNA specific to medullary carcinoma. To define the miRNA-based assay, the authors analyzed a training set of 375 FNAC cases that was validated using a blinded, multicenter, retrospective cohort of 201 validation smears with their corresponding surgical specimens. To select the set of miRNAs for classification, several screening stages were performed. In the first stage, 53 histological samples, 73 cell blocks of FNAC and 156 stained FNAC were profiled on Agilent custom-designed miRNA microarrays containing over 2000 miRNA probes. 92 Next, after a selection of 96 miRNAs that showed differential expression in benign and malignant tumors, a final set of 24 miRNAs was adopted. Lithwick-Yanai et al 92 highlighted the high level of reproducibility and concordance of yields (93% to 96%) in different laboratories and the advantage of using an existing diagnostic slide for molecular testing. Furthermore, the assay can be run on FNA slides with as little as 1% of thyroid cells present or from which only 5 ng of RNA is extracted. The authors found that the performance of the validation set was very similar to the performance estimates of the training set, showing 85% sensitivity, 72% specificity, 91% NPV, and 59% PPV.
Based on their results, Lithwick-Yanai et al, 92 using the miRNA-based assay, showed that the sensitivity and specificity of the subset of Bethesda III and IV samples were both 74%, with a NPV of 92% and PPV of 43%. Concerning samples of follicular adenoma with oncocytic features, the accuracy was slightly lower than that of nononcocytic follicular adenoma samples; however, this difference was not statistically significant.
ThyGenX and ThyraMIR
The ThyGenX (Interpace Diagnostics, Parsippany, NJ) thyroid 8-gene panel can be defined as a "newer version" of the original gene panel test used to detect genetic alterations. This commercial test, formerly known as miRInform (Asuragen, Austin, Texas), uses NGS technology. ThyGenX differs from Asuragen by its methodology, which consists of total nucleic acid extraction from RNARetain-preserved (Asuragen) FNAs using a proprietary, laboratory-validated method and quantified using a NanoDrop ND1000 spectrophotometer (NanoDrop Technologies, Waltham, Massachusetts). 93 The detection of BRAF V600E or RET/PTC is associated with 100% ROM, but it is lower and wider for RAS (range, 12% to 87.5%) and PAX8/PPARg (range, 50% to Cancer Cytopathology August 2018 100%) alterations. However, a wild-type test for an AUS/ FLUS sample would be slightly higher than that of a benign lesion, even though the ROM for a negative SFN/ FN sample would be identical to the nontested cases. In this regard, the problem with the limited ThyGenX panel alone is that wild-type results slightly decreased the ROM, but not enough to be comparable to a cytologically benign aspirate.
For this reason, Interpace Diagnostics suggest using ThyraMIR (also from Interpace Diagnostics, Parsippany, New Jersey) as a reflex test for those cases with wild-type/negative ThyGenX result that are not BRAF V600E -or RET/PTC 1-3 positive. 93 ThyraMIR is a thyroid miRNA classifier that is able to divide results into "positive" or "negative" categories. 93, 94 miRNA are defined as small, endogenous, noncoding RNA that act mainly as a negative posttranscriptional regulator of coding gene expression whose deregulation is frequently associated with different human cancers. [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] The majority of studies that have dealt with the role of miRNAs have involved specimens that were obtained from ex vivo thyroid aspiration during thyroidectomies in malignant and benign thyroid lesions. [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] The application of miRNA panels has since been extended to include indeterminate lesion categories. [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] Different authors have documented aberrant expression of specific miRNAs (eg, miR-146, -221, and -222) as a clue to thyroid well-differentiated carcinomas. [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] The evaluation of miRNAs has been performed successfully on different cytological material. 70, 72, 76 However, there were some discrepancies in diagnostic accuracy, sensitivity, and specificity. For example, Rossi et al 76 documented only 1 false negative case compared with 16 false positive and 6 false negative cases found by Agretti et al. 72 This discrepancy might be due to the application of different miRNA panels in these 2 studies.
More recent work has shown that combination testing with ThyGenX and ThyraMIR is both highly sensitive and specific. There have been 2 different studies that combined these tests for indeterminate thyroid nodules. 93, 94 These studies demonstrated high sensitivity (94% for AUS/FLUS and 82% for SFN/FN) and specificity (80% for AUS/FLUS and 91% for SFN/FN), with a PPV of 74% and NPV of 94%. More recently, multipanel testing (MPT) has been advocated, involving a multipanel approach combining the ThyGenX panel with the ThyraMIR classifier. 94 Labourier et al 93 studied 28 AUS/ FLUS nodules and found that for the multiplatform mutation and miRNA test (MPT) (ie, ThyGenX and ThyraMIR) there was 94% sensitivity, 80% specificity, 68% PPV, and 97% NPV. The investigators concluded that the MPT would appreciably reduce the number of thyroid surgeries. In another study, Wylie et al 94 found
that, using an MPT combining the presence of 17 validated oncogenic gene alterations in the BRAF, RAS, RET, or PAX8 genes (using the Luminex 200 platform) and ThyraMIR classifier, the latter increased the diagnostic sensitivity by 30% to 39% and correctly classified 100% of benign nodules. The application of MPT not only provides important information about the presence of specific mutations, but also the prognostic relevance of some of these mutations. In fact, despite the rarity of the following genetic alterations in the AUS/FLUS category, the detection of a BRAF V600E mutation or TERT promoter mutation would suggest that total thyroidectomy might be acceptable.
93,94

SFM AND MOLECULAR TESTING
For the SFM category of thyroid nodules, morphology alone is associated with a high PPV of approximately 70% for malignancy, even though the recent introduction of NIFTP has lowered the malignancy risk to approximately 50% (range, 45% to 60%). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 52 Numerous authors have highlighted the limitation of molecular studies for SFM nodules, given the high ROM for this category. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] 43, [96] [97] [98] [99] According to the most recent ATA guideline recommendations, molecular testing should be performed in nodules that are SFM if the molecular results may alter the surgical decision making and extent of surgery. 53 The detection of specific sinister genetic alterations with ThyroSeq and/or ThyGenX/ThyraMIR may have both management implications for the extent of surgery needed and prognostic implications for patient follow-up and risk of recurrence. Of note, because this category also includes malignancies other than PTC, ancillary studies in addition to molecular testing (eg, immunocytochemistry) can be very helpful from a diagnostic standpoint. 99 In the series of 1056 indeterminate lesions studied by Nikiforov et al, 32 the investigators included 67 cases of SFM, 51 of which had histological follow-up and 54% of which had a malignant outcome. [100] [101] [102] [103] indicate that BRAF V600E mutated PTC may be identified by certain distinctive morphological features, including architectural (eg, tumor-associated stromal reaction, infiltrative tumor borders) and cellular parameters (eg, nuclear features and polygonal eosinophilic cells defined as "plump cells"). This discovery has raised interest in evaluating cytological series of thyroid lesions for similar findings. [101] [102] [103] Indeed, the investigators found that mutated BRAF V600E cells showed "plump features" characterized by large polygonal tumor cells with cell height less than twice the width and had squamoid-like metaplasia with homogeneous, eosinophilic, moderate to abundant cytoplasm, and that they shared nuclear features of PTC (Fig. 4) . Furthermore, the same investigators discovered that peculiar nuclear shape (sickle-shaped nuclei) is associated with 100% of BRAF V600E cases, which is absent in the BRAF wild-type counterpart. Furthermore, Kwon et al, 41 in a series of 142 SM cases, similarly corroborated that cytomorphologic features can help select nodules that have a BRAF V600E mutation. According to Jara et al, 104 the detection of BRAF mutation in SFM nodules is of great value for preoperatively determining the extent of surgery required. As mentioned previously, in 2014 Veracyte added 2 malignant classifiers to their testing: Afirma MTC and Afirma BRAF, which are both mRNA classifiers, similar to the Afirma GEC. Afirma MTC has the ability to identify the gene expression signature of MTC; Afirma BRAF identifies the BRAF V600E mutation. Veracyte suggested that these tests might be useful for the SFM category or also cases in the positive for malignancy category. The usefulness of the BRAF mutation is still controversial, even though some authors correlated BRAF mutation with more aggressive behavior (eg, lymph node metastases and extrathyroid infiltration). 22, 26, 38, 39, 99 
NIFTP AND MOLECULAR TESTING
Noninvasive encapsulated follicular variant of papillary thyroid carcinoma (NE-FVPTC) was recently reclassified as NIFTP. 55 As shown in the second edition of the Bethesda thyroid system, this new terminology has decreased the ROM in most of the TBSRTC categories, most significantly in the indeterminate categories. [56] [57] [58] [59] [60] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] Some studies have demonstrated that NIFTP can indeed be differentiated from PTC in cytological samples. [108] [109] [110] The presence of nuclear pseudoinclusions and papillary structures are more typical features of PTC, whereas a predominantly follicular pattern and less frequent nuclear elongations and grooves are more likely to be associated with NIFTP. 56, 108 According to published series, the majority of NIFTP nodules are frequently diagnosed in the categories of AUS/FLUS (31.2%), SFN/FN (26.6%), and SM (24.3%). [56] [57] [58] [59] [60] [107] [108] [109] [110] [111] [112] [113] [114] for which the best suggested treatment is lobectomy. Caution should be recommended in cases of follicular proliferations with atypia to avoid overtreatment.
Molecular testing has been evaluated to try discriminate NIFTP from other neoplasms. [110] [111] [112] [113] [114] The initial prospective validated GEC study did not consider NIFTP, and only few papers have evaluated the impact of NIFTP on the performance of GEC. The diagnostic role of the Afirma test to detect NIFTP has been controversial. 42 mutations reported in some Korean series may be linked with less strict morphological inclusion and exclusion criteria. It is clear that the ongoing effort to reclassify encapsulated FVPC is impacting the landscape of molecular testing for indeterminate thyroid FNAC. Therefore, test panels that preoperatively distinguish molecular profiles will be increasingly helpful and relevant in guiding the most appropriate treatment options for these patients.
CONCLUSION
Indeterminate lesions of the thyroid are challenging in cytopathology practice. Although the majority of these nodules are due to benign histologic entities, they remain difficult to classify definitively on cytomorphology alone. Fortunately, the application of ancillary molecular testing for indeterminate thyroid FNA results has provided better risk stratification and has reduced the need for diagnostic thyroid surgery (Fig. 5) . Several mutation analysis panels are not only helpful as diagnostic tests, but may also serve as prognostic markers. There have been 3 leading approaches to the molecular characterization of FNA aspirates, including 1) the identification of specific molecular markers of malignancy (eg, BRAF, RAS mutations), 2) mRNA classifiers, and 3) miRNA classifiers. Mutational assays that analyze a broader Furthermore, the introduction of new entities such as NIFTP alters our understanding of thyroid pathology and with it the need to adjust diagnosis, prognosis, and treatment. Further studies with larger cohorts of NIFTP are necessary to better define the molecular profile of this entity.
In conclusion, molecular testing has shown great promise in reducing the diagnostic uncertainty of indeterminate nodules but at present should still be performed in the context of clinical, radiological, and cytological findings. In conclusion, regardless of the specific application of different commercial molecular tests, Table 5 summarizes some practical questions and doubts that are frequently associated with the molecular results.
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